Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX10 plus carboplatin and etoposide for previously untreated extensive-stage small cell lung cancer in Japanese patients
jRCT2071240133Phase 2Active, not recruiting
- Sponsor
- Henlius
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in small cell lung cancer (SCLC), sponsored by Henlius. Primary endpoint: Response (CR or PR) rate at week 24. Started May 2025; status: active, not recruiting.
02
Drugs
serplulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2071240133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240133.